Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636144 | 1.00 | ACHE (0.46) | ACHELMNAGAACHRM2CHRM4 | |
| SCHEMBL11752286 | 1.00 | ACHE (0.46) | ACHELMNAGAACHRM2CHRM4 | |
| SCHEMBL22326322 | 1.00 | ACHE (0.46) | ACHELMNAGAACHRM2CHRM4 | |
| SCHEMBL23152128 | 1.00 | ACHE (0.46) | ACHELMNAGAACHRM2CHRM4 | |
| SCHEMBL1132887 | 0.97 | — | — | |
| SCHEMBL28612804 | 0.91 | GAA (0.52) | ACHELMNAGAACHRM2CHRM4 | |
| SCHEMBL88487 | 0.90 | — | — | |
| SCHEMBL5721317 | 0.89 | TSHR (0.50) | ACHELMNACHRM2CHRM4CHRM5 | |
| SCHEMBL2059697 | 0.89 | TSHR (0.50) | ACHELMNACHRM2CHRM4CHRM5 | |
| SCHEMBL2136691 | 0.89 | TSHR (0.50) | ACHELMNACHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486759-A | Method for preparing methyl glutarimate by using furfuryl amine as raw material | 河北工业大学 | 2024-02-02 | — | — | CN | claimed |
| CN-113788830-B | Fluorescent probe compound and preparation method and application thereof | 湖南农业大学 | 2022-08-09 | — | — | CN | claimed |
| CN-113788830-A | Fluorescent probe compound and preparation method and application thereof | 湖南农业大学 | 2021-12-14 | — | — | CN | claimed |
| US-4062889-A | Preparation of sulfonylureas | ERIC LUCIEN | 1977-12-13 | — | — | US | claimed |
| CN-118176194-A | Conjugates comprising covalent binding agents for targeting intracellular proteins | 瑞择生物公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11998608-B2 | Polysaccharide and methods | THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS (GB) | 2024-06-04 | — | — | US | disclosed |
| CN-118019750-A | Drug delivery system for local delivery of therapeutic agents and uses thereof | 上海椿安生物医药科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117964623-A | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117924327-A | Kras inhibitor compounds having macrocyclic structure | 上海湃隆生物科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-113924288-B | Quinolinyl-containing compound, pharmaceutical composition and application thereof | 北京普祺医药科技股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117693507-A | Inhibitor compounds | 奈奥芬莱有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2024046443-A1 | MACROCYCLIC COMPOUNDS AS SELECTIVE CDK INHIBITORS | NUTSHELL BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-03-07 | — | — | WO | disclosed |
| US-5652247-A | VASOPRESSIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 1997-07-29 | — | — | US | disclosed |
| US-5436254-A | Vaopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0299566-A2 | Novel substituted N-(3-hydroxy-4-piperidinyl)benzamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-18 | — | — | EP | disclosed |
| US-4085129-A | FROM A PHENOL, DIALKYLAMIDE AND PHOSGENE | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998608-B2 | Polysaccharide and methods | CAP1, C1S, DDOST | ACHE 3779/4885LMNA 1108/4885GAA 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.